More Topics:
Nuovo Biologics Completes $1M Equity Offering - cbl
Posted April 20, 2011
We Recommend...
Gregoryi Carney
By Richard Rabicoff
MIAMI -- Animal drug developer Nuovo Biologics LLC completed an equity offering of $1 million.
According to the amended SEC filing, the company expanded the offering goal from $700,000. In January, citybizlist reported that Miami-based Nuovo Biologics raised $500,000 toward that target.
Named in the filing were CEO and CFO .
Previously, Yourist was a founder and CEO of CRP Network, LLC performing clinical research for the pharma industry. Before that, he served as the director of the Division of Vocational Rehabilitation and the Social Security Office of Disability Determination for the State of Florida. There he was also responsible to manage the state's head and spinal cord injury programs.
According to the company website, Chairman , CPA, has also invested in the company. Denkhaus is Chairman/Chief Financial Officer of TM Systems, LLC, a privately-held company that provides language dubbing and subtitling services primarily to the television industry. He is a board member of Eleven11 by Design, LLC, a privately-held company that sells action sports merchandise and provides event management. He spent more than 30 years at Arthur Andersen.
Nuovo's signature product is Panavira, a drug designed to treat viral related diseases in animals such as cats, dogs, birds and horses.
The company has set aside $120,000 from the offering proceeds to pay salaries of the named executive officers.
SEC filing: http://tinyurl.com/3fmmfx5
Bio
Gregory A. Carney
Chief Financial Officer
Mr. Carney is a highly experienced and versatile executive who for 30 years has delivered key services in mission critical areas at large and small organizations in both the Public and Private Sectors. He has held the positions of Partner, Senior Vice President, Director, or Chief Executive Officer in Information Technology, Telecommunications, Professional Services, Engineering, and E-commerce companies. Building on a base of over 20 years in management and information systems consulting, many of them as a Partner in Accenture LLC (previously Andersen Consulting), he has acted in a Chief Executive role with an E-commerce consulting company, and more recently spent five years with a UNEP based Competitive Local Exchange Carrier in the telecommunications market space working in almost all operational and administrative areas. Mr. Carney has worked for investor groups doing planning and due diligence efforts during acquisitions and has also been the CEO of a construction claims management and litigation support firm.
Mr. Carney has a Bachelor of Science degree in Mathematics from Carnegie-Mellon University. He has also done post-graduate studies in the Mellon Graduate School of Industrial Administration at C-MU specializing in Systems Science. Mr. Carney has served on various Boards of Directors over the years.
Also at citybizlist, see:
Nuovo Biologics Raises Most of $700K Share Offering - cbl
To find out more about the company in this article and to see if you
have business connections, click below:
blog comments powered by